DE3306250A1 - Sphaerische einkristalle fuer pharmazeutische zwecke - Google Patents
Sphaerische einkristalle fuer pharmazeutische zweckeInfo
- Publication number
- DE3306250A1 DE3306250A1 DE19833306250 DE3306250A DE3306250A1 DE 3306250 A1 DE3306250 A1 DE 3306250A1 DE 19833306250 DE19833306250 DE 19833306250 DE 3306250 A DE3306250 A DE 3306250A DE 3306250 A1 DE3306250 A1 DE 3306250A1
- Authority
- DE
- Germany
- Prior art keywords
- solution
- spherical
- single crystals
- crystals
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 41
- 239000007787 solid Substances 0.000 claims abstract description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 8
- 229940127557 pharmaceutical product Drugs 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 abstract description 27
- 239000000243 solution Substances 0.000 abstract description 19
- 238000000034 method Methods 0.000 abstract description 14
- 239000011248 coating agent Substances 0.000 abstract description 13
- 238000000576 coating method Methods 0.000 abstract description 13
- 239000007864 aqueous solution Substances 0.000 abstract description 5
- 238000011049 filling Methods 0.000 abstract description 5
- 238000001704 evaporation Methods 0.000 abstract description 2
- 230000008020 evaporation Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 229920006395 saturated elastomer Polymers 0.000 abstract description 2
- 238000010583 slow cooling Methods 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000007903 gelatin capsule Substances 0.000 abstract 1
- 238000010899 nucleation Methods 0.000 abstract 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 36
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 239000003826 tablet Substances 0.000 description 19
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- 239000001103 potassium chloride Substances 0.000 description 18
- 235000011164 potassium chloride Nutrition 0.000 description 18
- 239000000047 product Substances 0.000 description 16
- 239000008188 pellet Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 11
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 11
- 239000002775 capsule Substances 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 235000019341 magnesium sulphate Nutrition 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000009826 distribution Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
- 239000001828 Gelatine Substances 0.000 description 6
- 238000005299 abrasion Methods 0.000 description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 6
- 239000007938 effervescent tablet Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000004051 gastric juice Anatomy 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 238000001816 cooling Methods 0.000 description 5
- 239000012047 saturated solution Substances 0.000 description 5
- 239000012798 spherical particle Substances 0.000 description 5
- 239000001856 Ethyl cellulose Substances 0.000 description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000019325 ethyl cellulose Nutrition 0.000 description 4
- 229920001249 ethyl cellulose Polymers 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000004922 lacquer Substances 0.000 description 4
- 239000003973 paint Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000002966 varnish Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229910021485 fumed silica Inorganic materials 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- BLEBFDYUDVZRFG-UHFFFAOYSA-N dichloromethane;propan-2-ol Chemical compound ClCCl.CC(C)O BLEBFDYUDVZRFG-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 238000007440 spherical crystallization Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
Landscapes
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Metallurgy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Oxygen, Ozone, And Oxides In General (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Jellies, Jams, And Syrups (AREA)
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19833306250 DE3306250A1 (de) | 1983-02-23 | 1983-02-23 | Sphaerische einkristalle fuer pharmazeutische zwecke |
| AT84101627T ATE40291T1 (de) | 1983-02-23 | 1984-02-16 | Sphaerische einkristalle fuer pharmazeutische zwecke. |
| EP84101627A EP0119480B1 (de) | 1983-02-23 | 1984-02-16 | Sphärische Einkristalle für pharmazeutische Zwecke |
| DE8484101627T DE3476337D1 (en) | 1983-02-23 | 1984-02-16 | Spherical monocrystals for pharmaceutical use |
| CA000447819A CA1220421A (en) | 1983-02-23 | 1984-02-20 | Process for the preparation of solid pharmaceutical products |
| US06/581,714 US4632843A (en) | 1983-02-23 | 1984-02-21 | Process for the preparation of solid pharmaceutical products |
| IL71018A IL71018A (en) | 1983-02-23 | 1984-02-21 | Solid pharmaceutical products containing spherical single crystals and preparation thereof |
| ES529959A ES529959A0 (es) | 1983-02-23 | 1984-02-22 | Procedimiento para la obtencion de productos farmaceuticos solidos a base de particulas esfericas. |
| PT78146A PT78146B (en) | 1983-02-23 | 1984-02-22 | Process for the preparation of solid pharmaceutical compositions |
| AU24843/84A AU561079B2 (en) | 1983-02-23 | 1984-02-22 | Spherical single crystal solid pharmaceutical products |
| ZA841287A ZA841287B (en) | 1983-02-23 | 1984-02-22 | Process for the preparation of solid pharmaceutical products |
| JP59031552A JPS59182290A (ja) | 1983-02-23 | 1984-02-23 | 固形薬剤及びその製法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19833306250 DE3306250A1 (de) | 1983-02-23 | 1983-02-23 | Sphaerische einkristalle fuer pharmazeutische zwecke |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3306250A1 true DE3306250A1 (de) | 1984-08-23 |
Family
ID=6191601
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19833306250 Withdrawn DE3306250A1 (de) | 1983-02-23 | 1983-02-23 | Sphaerische einkristalle fuer pharmazeutische zwecke |
| DE8484101627T Expired DE3476337D1 (en) | 1983-02-23 | 1984-02-16 | Spherical monocrystals for pharmaceutical use |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8484101627T Expired DE3476337D1 (en) | 1983-02-23 | 1984-02-16 | Spherical monocrystals for pharmaceutical use |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4632843A (enExample) |
| EP (1) | EP0119480B1 (enExample) |
| JP (1) | JPS59182290A (enExample) |
| AT (1) | ATE40291T1 (enExample) |
| AU (1) | AU561079B2 (enExample) |
| CA (1) | CA1220421A (enExample) |
| DE (2) | DE3306250A1 (enExample) |
| ES (1) | ES529959A0 (enExample) |
| IL (1) | IL71018A (enExample) |
| PT (1) | PT78146B (enExample) |
| ZA (1) | ZA841287B (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4844910A (en) * | 1986-12-02 | 1989-07-04 | Euroceltique, S.A. | Spheroids |
| EP1020185A3 (de) * | 1999-01-18 | 2000-09-27 | Grünenthal GmbH | Opioide Analgetika mit kontrollierter Wirkstofffreisetzung |
| DE10218106A1 (de) * | 2002-04-23 | 2003-11-20 | Jenapharm Gmbh | Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen |
| DE10218110A1 (de) * | 2002-04-23 | 2003-11-20 | Jenapharm Gmbh | Verfahren zum Herstellen von Kristallen von Arzneimittelhilfsstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2038669T3 (es) * | 1986-09-18 | 1993-08-01 | London School Of Pharmacy Innovations Ltd | Formulacion farmaceutica. |
| US4874613A (en) * | 1987-03-06 | 1989-10-17 | Baker Cummins Pharmaceuticals, Inc. | Taste concealing pharmaceutical dosage unit |
| FR2613619B1 (fr) * | 1987-04-07 | 1993-10-15 | Recherche Informatique Pharmacie | Medicaments, produits dietetiques ou produits d'hygiene sous forme de compositions pulverulentes obtenues par adsorption de principes actifs sur un sucre a dissolution rapide |
| IL86211A (en) * | 1987-05-04 | 1992-03-29 | Ciba Geigy Ag | Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation |
| GB8805695D0 (en) * | 1988-03-10 | 1988-04-07 | Nycomed As | Enteric coated spheroidal granules |
| DE3911069A1 (de) * | 1989-04-06 | 1990-10-11 | Knoll Ag | Einkristalle von ss-phenylpropiophenonen |
| DE4027927A1 (de) * | 1990-09-04 | 1992-03-05 | Bayer Ag | Brausekomponente und verfahren zu ihrer herstellung |
| JP3447042B2 (ja) * | 1997-07-23 | 2003-09-16 | フロイント産業株式会社 | 単一物質球形粒の製造方法 |
| DE19834876A1 (de) * | 1998-08-01 | 2000-02-03 | Aventis Res & Tech Gmbh & Co | Verfahren zur Herstellung sphärischer Teilchen bei der Kristallisation |
| EP1189599A2 (en) * | 1999-06-11 | 2002-03-27 | Eli Lilly And Company | Pharmaceutical materials and methods for their preparation and use |
| US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
| FI20002217A7 (fi) * | 1999-12-30 | 2001-07-01 | Orion Yhtymae Oyj | Inhalaatiopartikkelit |
| FI20010115A0 (fi) * | 2001-01-18 | 2001-01-18 | Orion Corp | Menetelmä nanopartikkelien valmistamiseksi |
| JP4422488B2 (ja) * | 2002-02-19 | 2010-02-24 | テバ ファーマシューティカル インダストリーズ リミティド | アトルバスタチンヘミカルシウム溶媒和物の脱溶媒和法及び有機溶媒を本質的に含まないアトルバスタチンヘミカルシウム |
| US20040028729A1 (en) * | 2002-04-29 | 2004-02-12 | Shojaei Amir H. | Pharmaceutical formulations with improved bioavailability |
| AT504996B1 (de) * | 2007-03-02 | 2009-03-15 | Andritz Tech & Asset Man Gmbh | Verfahren und vorrichtung zur trocknung von kristallinen carbonsäuren |
| US20080268018A1 (en) * | 2007-04-30 | 2008-10-30 | Pacetti Stephen D | Method for forming crystallized therapeutic agents on a medical device |
| US9149434B2 (en) * | 2007-12-03 | 2015-10-06 | Tomita Pharmaceutical Co., Ltd. | Core particle for pharmaceutical preparation |
| CA2691554A1 (en) * | 2010-02-01 | 2011-08-01 | Michael Krautter | Crystal growing device |
| US9905953B1 (en) | 2016-09-30 | 2018-02-27 | Slobodan Pavlovic | High power spring-actuated electrical connector |
| KR20190065344A (ko) * | 2016-10-03 | 2019-06-11 | 회가내스 아베 (피유비엘) | 백색 철 식품 첨가제 |
| JP6989715B2 (ja) | 2018-02-26 | 2022-01-05 | ロイヤル プレシジョン プロダクツ，エルエルシー | 高電力用途用のばね作動式電気コネクター |
| CN111498874B (zh) * | 2020-02-21 | 2022-10-04 | 天津大学 | 一种大粒度碘化铯球晶及其制备方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA799930A (en) * | 1968-11-26 | Polderman Jacobus | Process for rendering powders free flowing and the thus obtained powders | |
| US2996431A (en) * | 1953-12-16 | 1961-08-15 | Barry Richard Henry | Friable tablet and process for manufacturing same |
| US2853420A (en) * | 1956-01-25 | 1958-09-23 | Lowey Hans | Ethyl cellulose coatings for shaped medicinal preparations |
| US3072533A (en) * | 1960-11-15 | 1963-01-08 | Henry J Johnson | Crystalline vitamin d composition and method of preparing same |
| NL137432C (enExample) * | 1964-08-13 | 1900-01-01 | ||
| US3433872A (en) * | 1966-11-25 | 1969-03-18 | Hoffmann La Roche | Palatable,free-flowing,non-agglomerating caffeine powder |
| FR7932M (enExample) * | 1968-09-30 | 1970-05-19 | ||
| US3854480A (en) * | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| CA942667A (en) * | 1970-10-16 | 1974-02-26 | Alejandro Zaffaroni | Drug-delivery system |
| US3909444A (en) * | 1971-08-05 | 1975-09-30 | Ncr Co | Microcapsule |
| FR2171934B1 (enExample) * | 1972-02-16 | 1974-09-13 | Rhone Poulenc Sa | |
| US4123382A (en) * | 1973-05-25 | 1978-10-31 | Merck & Co., Inc. | Method of microencapsulation |
| JPS53124634A (en) * | 1974-08-15 | 1978-10-31 | Shin Nihon Kagaku Kogyo Kk | Production of table salt |
| JPS51113813A (en) * | 1975-03-03 | 1976-10-07 | Towa Kasei Kogyo Kk | Pulverizing process of maltitol |
| SE418247B (sv) * | 1975-11-17 | 1981-05-18 | Haessle Ab | Sett att framstella kroppar med reglerad frigoring av en aktiv komponent |
| DD146547A5 (de) * | 1978-07-15 | 1981-02-18 | Boehringer Sohn Ingelheim | Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen |
| US4386120A (en) * | 1980-01-07 | 1983-05-31 | Nippon Kayaku Kabushiki Kaisha | Process for producing polyacrylic acid salt granules easily soluble in water |
| DE3000979A1 (de) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| US4259315A (en) * | 1980-06-13 | 1981-03-31 | A. H. Robins Company, Inc. | Controlled release potassium dosage form |
| US4479911A (en) * | 1982-01-28 | 1984-10-30 | Sandoz, Inc. | Process for preparation of microspheres and modification of release rate of core material |
-
1983
- 1983-02-23 DE DE19833306250 patent/DE3306250A1/de not_active Withdrawn
-
1984
- 1984-02-16 AT AT84101627T patent/ATE40291T1/de not_active IP Right Cessation
- 1984-02-16 DE DE8484101627T patent/DE3476337D1/de not_active Expired
- 1984-02-16 EP EP84101627A patent/EP0119480B1/de not_active Expired
- 1984-02-20 CA CA000447819A patent/CA1220421A/en not_active Expired
- 1984-02-21 IL IL71018A patent/IL71018A/xx not_active IP Right Cessation
- 1984-02-21 US US06/581,714 patent/US4632843A/en not_active Expired - Lifetime
- 1984-02-22 ES ES529959A patent/ES529959A0/es active Granted
- 1984-02-22 PT PT78146A patent/PT78146B/pt unknown
- 1984-02-22 ZA ZA841287A patent/ZA841287B/xx unknown
- 1984-02-22 AU AU24843/84A patent/AU561079B2/en not_active Expired
- 1984-02-23 JP JP59031552A patent/JPS59182290A/ja active Granted
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4844910A (en) * | 1986-12-02 | 1989-07-04 | Euroceltique, S.A. | Spheroids |
| EP1020185A3 (de) * | 1999-01-18 | 2000-09-27 | Grünenthal GmbH | Opioide Analgetika mit kontrollierter Wirkstofffreisetzung |
| US6685964B1 (en) | 1999-01-18 | 2004-02-03 | Gruenenthal Gmbh | Opioid analgesics with controlled active substance release |
| DE10218106A1 (de) * | 2002-04-23 | 2003-11-20 | Jenapharm Gmbh | Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen |
| DE10218110A1 (de) * | 2002-04-23 | 2003-11-20 | Jenapharm Gmbh | Verfahren zum Herstellen von Kristallen von Arzneimittelhilfsstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3476337D1 (en) | 1989-03-02 |
| IL71018A (en) | 1987-01-30 |
| ZA841287B (en) | 1984-10-31 |
| ES8504452A1 (es) | 1985-04-16 |
| PT78146A (en) | 1984-03-01 |
| CA1220421A (en) | 1987-04-14 |
| JPS59182290A (ja) | 1984-10-17 |
| PT78146B (en) | 1986-05-19 |
| AU2484384A (en) | 1984-08-30 |
| US4632843A (en) | 1986-12-30 |
| ES529959A0 (es) | 1985-04-16 |
| JPH0573727B2 (enExample) | 1993-10-15 |
| EP0119480A3 (en) | 1985-09-25 |
| EP0119480B1 (de) | 1989-01-25 |
| EP0119480A2 (de) | 1984-09-26 |
| AU561079B2 (en) | 1987-04-30 |
| ATE40291T1 (de) | 1989-02-15 |
| IL71018A0 (en) | 1984-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0119480B1 (de) | Sphärische Einkristalle für pharmazeutische Zwecke | |
| DE69026555T2 (de) | Feste zubereitung von aktivem vitamin d3 mit verbesserter stabilität | |
| DE68903846T2 (de) | Neue galenische form von fenofibrat. | |
| DE60004649T2 (de) | Verfahren zur herstellung nicht-hygroscopische l (-) - carnitine salze | |
| DE68916497T2 (de) | Pharmazeutisches Granulat. | |
| EP0212537B1 (de) | Verfahren zur Herstellung einer stabilen Modifikation von Torasemid sowie Arzneimittel enthaltend Torasemid | |
| DE68902531T2 (de) | Dispergierbare zubereitung. | |
| DD285720A5 (de) | Verfahren zur herstellung einer saeurebindenden, aufschaeumenden zubereitung | |
| DE2813146A1 (de) | Tablettieren von mikrokapseln | |
| DE69108022T3 (de) | Arzneimittel. | |
| DE69712100T2 (de) | Valproinsäure enthaltende mikrosphären für orale verabreichung | |
| DE60008508T3 (de) | Agglomerate durch kristallisation | |
| DE3687317T2 (de) | Verfahren zur herstellung von brausemischungen. | |
| EP0642784A1 (de) | Brausemischung mit Alkalisalzen oder Lysinaten saurer, unlöslicher oder schwer löslicher Wirkstoffe | |
| DE69002186T2 (de) | Kalziumpantothenatzusammensetzung. | |
| DE2348334A1 (de) | Neue zubereitungsform des n-4- eckige klammer auf 2-(5-chlor-2-methoxybenzamido)aethyl eckige klammer zu -phenyl-sulfonyln'-cyclohexylharnstoffs | |
| EP0665830B1 (de) | Tilidin-dihydrogenorthophosphat, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen | |
| EP0641200B1 (de) | 2-arylpropionsäure-zubereitungen und verfahren zu ihrer herstellung | |
| DE69214333T2 (de) | Arzneizubereitung mit hohem Gehalt an Ibuprofenlysinat | |
| DE3833448A1 (de) | Verfahren zur gewinnung von ibuprofen fuer die direkttablettierung | |
| DE2629200C2 (enExample) | ||
| DE3325652C2 (enExample) | ||
| DE69103724T2 (de) | Pharmazeutische zusammensetzungen mit verzögerter freisetzung zur oralen verabreichung sowie deren herstellungsverfahren. | |
| EP0164587A2 (de) | Nifedipinpräparate und Verfahren zu ihrer Herstellung | |
| DE1617468A1 (de) | Verfahren zur Herstellung von Acetylsalicylsaeure-Suspensionen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8141 | Disposal/no request for examination |